OSI board rejects Astellas' $3.5 billion offer Belleville News Democrat OSI received most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells in partnership with Genentech, which is now part of Roche. ...
Amy Van Sciver phillyBurbs.com Amy Van Sciver passed away on Sunday, March 14, 2010, following a valiant and courageous struggle with pancreatic cancer. She was born on Aug. ...
OSI board rejects Astellas' $3.5 billion offer Bismarck Tribune OSI received most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells in partnership with Genentech, which is now part of Roche. ...
New documentary looks at Bill Hicks San Antonio Express In his short life Hicks was 32 when he died of pancreatic cancer in 1994 he raged against prevailing attitudes on religion, sex, drugs, ...
OSI board rejects Astellas' $3.5 billion offer San Francisco Chronicle OSI received most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells in partnership with Genentech, which is now part of Roche. ...
Apple gives its chief operating officer $5 million bonus 24masti (blog) Cook took the company reigns when Jobs went on a medical leave from January through June 2009 due to his pancreatic cancer. It was Cook's second time in ...
Ink now, worry later The Press West Coast ... here" is not in reference to Clarke, but instead a message for her late father Graham who died after a battle with liver and pancreatic cancer in 2008.
OSI board rejects Astellas' $3.5 billion offer KTVZ OSI received most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells in partnership with Genentech, which is now part of Roche. ...
OSI board rejects Astellas' $3.5 billion offer WBOC TV 16 OSI received most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells in partnership with Genentech, which is now part of Roche. ...
OSI board rejects Astellas' $3.5 billion offer York Daily Record OSI received most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells in partnership with Genentech, which is now part of Roche. ...
OSI board rejects Astellas' $3.5 billion offer Monterey County Herald OSI received most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells in partnership with Genentech, which is now part of Roche. ...
OSI looks for other buyers and rejects Astellas offer Pharma Times OSI's profits are a result of the success of the blockbuster Tarceva (erlotinib), which is co-marketed with Roche for lung and pancreatic cancer. ...
